GLP-1/Weight Loss

The Aesthetic Syndicate evolves into Manor, launching a national brand that fuses injectables with medically supervised GLP-1 therapy and holistic health.

A breakthrough study in a Nature journal reveals a novel device, RefluxStop, has a stellar long-term safety record, offering hope for millions with severe GERD.

The insurer is offering at-home defibrillators and health tech, aiming to redefine its role from covering death to extending life. But what does it mean for you?

European digital health firm Apomeds launches in the UK, targeting the booming telehealth market with a focus on discreet, high-demand treatments.

Biocon merges its biosimilar and generics units, appointing 30-year veteran Shreehas Tambe as CEO to forge a new globally-scaled biopharma enterprise.

Telehealth platforms like ReflexMD offer cheaper, compounded GLP-1s for weight loss. But what are the risks, and what do consumers need to know?

As its new obesity drug enters a key trial, Biohaven bets on a novel approach: reducing fat while preserving precious muscle mass. Can it redefine weight loss?

Tenax Therapeutics achieves a major clinical trial goal, moving its promising drug TNX-103 closer to becoming the first approved therapy for a deadly heart condition.

A new partnership leverages advanced AI and metabolomics to find novel drug targets for rare metabolic disorders, offering new hope for millions worldwide.

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

Verdiva Bio's VRB-101 aims to be the first once-weekly oral GLP-1, a potential game-changer for patients tired of daily pills and injections.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

A food-tech startup is challenging giants with snacks made from a revolutionary Harvard-developed tech, promising clean ingredients at unprecedented speed.

Facing massive revenue declines and a shrinking coach network due to GLP-1 drugs, Medifast bets its future on a risky pivot from weight loss to metabolic health.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

With surging revenues and a new body contouring system, Apyx Medical heads to the BTIG conference to prove its growth story is here to stay.

As employers pull back coverage for pricey weight-loss drugs, a new partnership offers a flexible way to provide access without breaking the budget.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.